S&P 500   3,970.99 (+0.56%)
DOW   32,237.53 (+0.41%)
QQQ   310.89 (+0.37%)
AAPL   160.25 (+0.83%)
MSFT   280.57 (+1.05%)
META   206.01 (+0.85%)
GOOGL   105.44 (-0.15%)
AMZN   98.13 (-0.59%)
TSLA   190.41 (-0.94%)
NVDA   267.79 (-1.52%)
NIO   9.07 (-2.16%)
BABA   86.90 (+0.44%)
AMD   97.95 (-2.32%)
T   18.61 (+0.81%)
F   11.51 (+0.79%)
MU   61.16 (-0.29%)
CGC   1.90 (-0.52%)
GE   91.37 (-0.24%)
DIS   94.08 (-1.83%)
AMC   4.47 (+0.00%)
PFE   40.39 (+0.52%)
PYPL   73.88 (+1.82%)
NFLX   328.39 (+2.50%)
S&P 500   3,970.99 (+0.56%)
DOW   32,237.53 (+0.41%)
QQQ   310.89 (+0.37%)
AAPL   160.25 (+0.83%)
MSFT   280.57 (+1.05%)
META   206.01 (+0.85%)
GOOGL   105.44 (-0.15%)
AMZN   98.13 (-0.59%)
TSLA   190.41 (-0.94%)
NVDA   267.79 (-1.52%)
NIO   9.07 (-2.16%)
BABA   86.90 (+0.44%)
AMD   97.95 (-2.32%)
T   18.61 (+0.81%)
F   11.51 (+0.79%)
MU   61.16 (-0.29%)
CGC   1.90 (-0.52%)
GE   91.37 (-0.24%)
DIS   94.08 (-1.83%)
AMC   4.47 (+0.00%)
PFE   40.39 (+0.52%)
PYPL   73.88 (+1.82%)
NFLX   328.39 (+2.50%)
S&P 500   3,970.99 (+0.56%)
DOW   32,237.53 (+0.41%)
QQQ   310.89 (+0.37%)
AAPL   160.25 (+0.83%)
MSFT   280.57 (+1.05%)
META   206.01 (+0.85%)
GOOGL   105.44 (-0.15%)
AMZN   98.13 (-0.59%)
TSLA   190.41 (-0.94%)
NVDA   267.79 (-1.52%)
NIO   9.07 (-2.16%)
BABA   86.90 (+0.44%)
AMD   97.95 (-2.32%)
T   18.61 (+0.81%)
F   11.51 (+0.79%)
MU   61.16 (-0.29%)
CGC   1.90 (-0.52%)
GE   91.37 (-0.24%)
DIS   94.08 (-1.83%)
AMC   4.47 (+0.00%)
PFE   40.39 (+0.52%)
PYPL   73.88 (+1.82%)
NFLX   328.39 (+2.50%)
S&P 500   3,970.99 (+0.56%)
DOW   32,237.53 (+0.41%)
QQQ   310.89 (+0.37%)
AAPL   160.25 (+0.83%)
MSFT   280.57 (+1.05%)
META   206.01 (+0.85%)
GOOGL   105.44 (-0.15%)
AMZN   98.13 (-0.59%)
TSLA   190.41 (-0.94%)
NVDA   267.79 (-1.52%)
NIO   9.07 (-2.16%)
BABA   86.90 (+0.44%)
AMD   97.95 (-2.32%)
T   18.61 (+0.81%)
F   11.51 (+0.79%)
MU   61.16 (-0.29%)
CGC   1.90 (-0.52%)
GE   91.37 (-0.24%)
DIS   94.08 (-1.83%)
AMC   4.47 (+0.00%)
PFE   40.39 (+0.52%)
PYPL   73.88 (+1.82%)
NFLX   328.39 (+2.50%)
Positive News Sentiment  
NASDAQ:CMPS

COMPASS Pathways - CMPS Stock Forecast, Price & News

$10.08
0.00 (0.00%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$9.88
▼
$10.24
50-Day Range
$7.75
▼
$10.85
52-Week Range
$6.54
▼
$21.50
Volume
361,756 shs
Average Volume
271,322 shs
Market Capitalization
$429.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$34.83

COMPASS Pathways MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
366.3% Upside
$47.00 Price Target
Short Interest
Bearish
10.77% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.92) to ($2.97) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.78 out of 5 stars

Medical Sector

905th out of 989 stocks

Pharmaceutical Preparations Industry

436th out of 480 stocks

See Top Rated MarketRank™ Stocks Here

CMPS stock logo

About COMPASS Pathways (NASDAQ:CMPS) Stock

COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Receive CMPS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for COMPASS Pathways and its competitors with MarketBeat's FREE daily newsletter.

CMPS Stock News Headlines

March 14, 2023 | markets.businessinsider.com
COMPASS Pathways: New Data & Insight On Psilocybin Therapy For Treatment-Resistant Depression
March 12, 2023 | finance.yahoo.com
10 Best Psychedelic Stocks to Buy According to Hedge Funds
March 24, 2023 | Weiss Ratings (Ad)
Bank Accounts: Frozen!
In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!
March 2, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Syros Pharmaceuticals (SYRS) and COMPASS Pathways (CMPS)
March 2, 2023 | finance.yahoo.com
COMPASS Pathways to participate in upcoming Cowen 43rd Annual Health Care Conference, Oppenheimer 33rd Annual Healthcare Conference, and Loop Capital Investor Conference
March 2, 2023 | finance.yahoo.com
COMPASS Pathways plc (NASDAQ:CMPS) Q4 2022 Earnings Call Transcript
March 2, 2023 | finance.yahoo.com
Anorexia is the deadliest psychiatric disorder. Could psychedelics help?
March 1, 2023 | finance.yahoo.com
Compass Pathways Plc (CMPS) Q4 2022 Earnings Call Transcript
March 24, 2023 | Oxford Club (Ad)
My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
March 1, 2023 | finance.yahoo.com
Q4 2022 Compass Pathways PLC Earnings Call
February 28, 2023 | finance.yahoo.com
COMPASS Pathways Announces Fourth Quarter and Year-End 2022 Financial Results and Business Highlights
February 28, 2023 | finance.yahoo.com
COMPASS Pathways Announces Fourth Quarter and Year-End 2022 Financial Results and Business Highlights
February 27, 2023 | msn.com
Earnings Preview: Compass Pathways
February 24, 2023 | finance.yahoo.com
COMPASS Pathways plc to announce fourth quarter and year-end 2022 financial results on 28 February 2023
February 20, 2023 | finance.yahoo.com
7 Long-Term Stocks to Buy With Your Tax Refund
February 16, 2023 | msn.com
Cybin, Compass Pathways Among Top Psychedelic Movers Of Today
February 8, 2023 | benzinga.com
COMPASS Pathways And The Economic Outlook For 2023
January 26, 2023 | seekingalpha.com
Compass Pathways Takes On Psychedelics
January 13, 2023 | finance.yahoo.com
All You Need to Know About COMPASS Pathways PLC Sponsored ADR (CMPS) Rating Upgrade to Strong Buy
January 11, 2023 | finance.yahoo.com
Are Medical Stocks Lagging COMPASS Pathways (CMPS) This Year?
December 12, 2022 | benzinga.com
Magic Mushrooms Tested For Treating Type II Bipolar Disorder, Check Out Results So Far
December 9, 2022 | msn.com
Psychedelics And Treatment-Resistant Depression: COMPASS Pathways Replies To Comments
December 8, 2022 | msn.com
Compass Pathways, Mind Medicine Among Top Psychedelic Movers Of Today
November 29, 2022 | finance.yahoo.com
3 Big Trends Shaking Up Psychedelic Stocks
November 28, 2022 | finance.yahoo.com
COMPASS Pathways to participate in upcoming Evercore ISI HealthCONx Conference
November 4, 2022 | finance.yahoo.com
REFILE-Magic mushroom compound shows promise as depression treatment in key study
November 3, 2022 | msn.com
Compass Pathways: Q3 Earnings Insights
See More Headlines
Receive CMPS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for COMPASS Pathways and its competitors with MarketBeat's FREE daily newsletter.

CMPS Company Calendar

Last Earnings
2/28/2023
Today
3/24/2023
Next Earnings (Estimated)
5/09/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CMPS
CUSIP
N/A
CIK
1816590
Web
www.compasspathways.com
Phone
716-676-6461
Fax
N/A
Employees
116
Year Founded
2016

Price Target and Rating

Average Stock Price Forecast
$47.00
High Stock Price Forecast
$120.00
Low Stock Price Forecast
$19.00
Forecasted Upside/Downside
+245.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.16)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-91,500,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-42.56%
Return on Assets
-39.25%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
12.29
Quick Ratio
12.29

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.26 per share
Price / Book
2.37

Miscellaneous

Outstanding Shares
42,630,000
Free Float
32,038,000
Market Cap
$429.71 million
Optionable
Not Optionable
Beta
2.46

Social Links


Key Executives

  • Mr. George Jay Goldsmith (Age 68)
    Exec. Chairman & Co-Founder
    Comp: $943.52k
  • Dr. Ekaterina Malievskaia M.D. (Age 55)
    Co-Founder, Chief Innovation Officer & Exec. Director
    Comp: $669.13k
  • Dr. Guy Goodwin
    Chief Medical Officer
  • Mr. Kabir Nath M.A.
    M.B.A., Chief Exec. Officer
  • Mr. Michael F. Falvey (Age 63)
    Chief Financial Officer
  • Dr. Greg Ryslik Ph.D.
    Exec. VP of AI, Engineering, Digital Health Research & Technology
  • Mr. Stephen D. Schultz
    Sr. VP of Investor Relations
  • Mr. Matthew Owens
    Gen. Counsel & Chief Legal Officer
  • Mr. Christopher Williams
    Chief Communications Officer
  • Ms. Anne Benedict
    Chief People Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













CMPS Stock - Frequently Asked Questions

Should I buy or sell COMPASS Pathways stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for COMPASS Pathways in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CMPS shares.
View CMPS analyst ratings or view top-rated stocks.

What is COMPASS Pathways' stock price forecast for 2023?

5 equities research analysts have issued 12 month price targets for COMPASS Pathways' stock. Their CMPS share price forecasts range from $19.00 to $120.00. On average, they anticipate the company's share price to reach $47.00 in the next twelve months. This suggests a possible upside of 368.6% from the stock's current price.
View analysts price targets for CMPS or view top-rated stocks among Wall Street analysts.

How have CMPS shares performed in 2023?

COMPASS Pathways' stock was trading at $8.03 on January 1st, 2023. Since then, CMPS stock has increased by 24.9% and is now trading at $10.03.
View the best growth stocks for 2023 here.

When is COMPASS Pathways' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our CMPS earnings forecast.

How were COMPASS Pathways' earnings last quarter?

COMPASS Pathways plc (NASDAQ:CMPS) issued its earnings results on Tuesday, February, 28th. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.65) by $0.08.

What ETFs hold COMPASS Pathways' stock?

ETFs with the largest weight of COMPASS Pathways (NASDAQ:CMPS) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL), Psyk Etf (PSYK), ARK Genomic Revolution ETF (ARKG), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Putnam Sustainable Future ETF (PFUT) and Grizzle Growth ETF (GRZZ).ALPS Medical Breakthroughs ETF (SBIO).

What other stocks do shareholders of COMPASS Pathways own?

Based on aggregate information from My MarketBeat watchlists, some companies that other COMPASS Pathways investors own include Nikola (NKLA), Vaxart (VXRT), Beyond Meat (BYND), Evofem Biosciences (EVFM), GrowGeneration (GRWG), McDonald's (MCD), Plug Power (PLUG), Block (SQ), Workhorse Group (WKHS) and

When did COMPASS Pathways IPO?

(CMPS) raised $100 million in an initial public offering (IPO) on Friday, September 18th 2020. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Cowen, Evercore ISI and Berenberg acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is COMPASS Pathways' stock symbol?

COMPASS Pathways trades on the NASDAQ under the ticker symbol "CMPS."

Who are COMPASS Pathways' major shareholders?

COMPASS Pathways' stock is owned by many different retail and institutional investors. Top institutional investors include ARK Investment Management LLC (2.89%), Susquehanna International Group LLP (0.00%), Morgan Stanley (0.77%), Sumitomo Mitsui Trust Holdings Inc. (0.75%), Nikko Asset Management Americas Inc. (0.75%) and Renaissance Technologies LLC (0.43%). Insiders that own company stock include David Y Norton and Ekaterina Malievskaia.
View institutional ownership trends.

How do I buy shares of COMPASS Pathways?

Shares of CMPS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is COMPASS Pathways' stock price today?

One share of CMPS stock can currently be purchased for approximately $10.03.

How much money does COMPASS Pathways make?

COMPASS Pathways (NASDAQ:CMPS) has a market capitalization of $427.58 million. The company earns $-91,500,000.00 in net income (profit) each year or ($2.16) on an earnings per share basis.

How many employees does COMPASS Pathways have?

The company employs 116 workers across the globe.

How can I contact COMPASS Pathways?

The official website for the company is www.compasspathways.com. The company can be reached via phone at 716-676-6461 or via email at ir@compasspathways.com.

This page (NASDAQ:CMPS) was last updated on 3/24/2023 by MarketBeat.com Staff